Q-omics provides the consensus-scored INHBE profile across patient tissues and cancer cell-line models. INHBE expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, INHBE is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, INHBE RNA expression shows 15,619 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, KIRC, and UVM as cancer lineages where INHBE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INHBE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INHBE survival associations across molecular data types. INHBE RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INHBE RNA expression–survival associations across cancer types. High INHBE expression shows unfavorable associations in KICH, ACC, KIRC, MESO, UCEC and UVM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for INHBE RNA expression.
This table summarizes INHBE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for INHBE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INHBE shows higher tumor expression in KIRC, HNSC, COAD, KIRP, UCEC and LUSC. The KIRC box plot shows higher INHBE RNA expression in tumor versus normal tissue (log2 FC = +2.007, t-test p < 0.001).
This table shows molecular features associated with INHBE in patient tissues and cancer cell lines. In patient samples, INHBE shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, INHBE RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
